Abstract
Mucopolysaccharidosis VI is an autosomal recessive lysosomal storage disorder associated with severe disability and premature death. The presence of a mucopolysaccharidosis-like disease in indigenous ethnic groups in Colombia can be inferred from archaeological findings. There are several indigenous patients with mucopolysaccharidosis VI currently receiving enzyme replacement therapy. We discuss the ethical and economic considerations, regarding both direct and indirect costs, of a high-cost orphan disease in a marginalised minority population in a developing country.
| Original language | English |
|---|---|
| Pages (from-to) | 699-700 |
| Number of pages | 2 |
| Journal | Journal of Medical Ethics |
| Volume | 38 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Ethical and economic considerations of rare diseases in ethnic minorities: The case of mucopolysaccharidosis VI in Colombia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver